

Sameek Roychowdhury

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6366057/publications.pdf>

Version: 2024-02-01

65
papers

7,534
citations

109321

35
h-index

114465

63
g-index

65
all docs

65
docs citations

65
times ranked

13574
citing authors

#	ARTICLE	IF	CITATIONS
1	Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake. <i>Familial Cancer</i> , 2023, 22, 91-97.	1.9	6
2	Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 351-364.	2.8	5
3	Characterization of Clonal Evolution in Microsatellite Unstable Metastatic Cancers through Multiregional Tumor Sequencing. <i>Molecular Cancer Research</i> , 2021, 19, 465-474.	3.4	2
4	Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. <i>British Journal of Cancer</i> , 2021, 124, 880-892.	6.4	150
5	Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100164.	1.1	6
6	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 803-815.	8.1	205
7	Research Autopsy Demonstrates Polyclonal Acquired Resistance in a Patient With Metastatic GI Stromal Tumor. <i>JCO Precision Oncology</i> , 2020, 4, 131-138.	3.0	3
8	Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trial. <i>Future Oncology</i> , 2020, 16, 2375-2384.	2.4	62
9	Co-occurrence of multiple endocrine neoplasia type 4 and spinal neurofibromatosis: a case report. <i>Familial Cancer</i> , 2020, 19, 189-192.	1.9	8
10	Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3117-3125.	7.0	13
11	Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 847-857.	4.1	91
12	Detection of Microsatellite Instability Biomarkers via Next-Generation Sequencing. <i>Methods in Molecular Biology</i> , 2020, 2055, 119-132.	0.9	42
13	Pan-cancer analysis of FGFR1-3 genomic alterations to reveal a complex molecular landscape. <i>Journal of Clinical Oncology</i> , 2020, 38, 3620-3620.	1.6	10
14	Implementing precision cancer medicine in the genomic era. <i>Seminars in Cancer Biology</i> , 2019, 55, 16-27.	9.6	24
15	Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004002.	1.2	60
16	Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 167-173.	2.0	9
17	Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 624-632.	3.9	5
18	Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers. <i>Thyroid</i> , 2019, 29, 523-529.	4.5	31

#	ARTICLE	IF	CITATIONS
19	Significant and Durable Clinical Response to Sorafenib and Radiation Therapy for a Patient With Stage IV Hepatocellular Carcinoma and LRRK2 Mutation. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	3.0	1
20	Rapid Research Autopsy: Piecing the Puzzle of Tumor Heterogeneity. <i>Trends in Cancer</i> , 2019, 5, 1-5.	7.4	13
21	Precision Cancer Medicine and Clinical Trial Design. , 2019, , 49-63.		2
22	Genomic characterization of metastatic ultra-hypermuted interdigitating dendritic cell sarcoma through rapid research autopsy. <i>Oncotarget</i> , 2019, 10, 277-288.	1.8	6
23	Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosity. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002352.	1.2	11
24	Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1008-1011.	1.3	29
25	Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1035-1040.	4.9	24
26	Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGI398. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 614-624.	4.1	72
27	Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 682-696.	2.8	56
28	Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffeyâ€ˆHolden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2017, 77, 123-144.	2.3	6
29	Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS. <i>Oncotarget</i> , 2017, 8, 7452-7463.	1.8	232
30	Landscape of Microsatellite Instability Across 39 Cancer Types. <i>JCO Precision Oncology</i> , 2017, 2017, 1-15.	3.0	796
31	Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer. <i>Oncotarget</i> , 2017, 8, 75822-75833.	1.8	6
32	Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer. <i>Cell Reports</i> , 2016, 17, 2620-2631.	6.4	68
33	The Bayesian basket design for genomic variant-driven phase II trials. <i>Seminars in Oncology</i> , 2016, 43, 13-18.	2.2	81
34	Translating cancer genomes and transcriptomes for precision oncology. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 75-88.	329.8	133
35	Somatic cancer variant curation and harmonization through consensus minimum variant level data. <i>Genome Medicine</i> , 2016, 8, 117.	8.2	61
36	Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	10

#	ARTICLE	IF	CITATIONS
37	Impact of genomic sequencing on precision medicine for clinical oncology. Expert Review of Precision Medicine and Drug Development, 2016, 1, 255-265.	0.7	0
38	Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories: Table 1.. Journal of the National Cancer Institute, 2016, 108, djv351.	6.3	86
39	Evaluation of Hybridization Capture Versus Amplicon-Based Methods for Whole-Exome Sequencing. Human Mutation, 2015, 36, 903-914.	2.5	206
40	Clinical Tumor Sequencing: Opportunities and Challenges for Precision Cancer Medicine. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e175-e182.	3.8	47
41	Cancer Driver Log (CanDL). Journal of Molecular Diagnostics, 2015, 17, 554-559.	2.8	56
42	Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. JAMA - Journal of the American Medical Association, 2015, 314, 913.	7.4	333
43	Comparison of Custom Capture for Targeted Next-Generation DNA Sequencing. Journal of Molecular Diagnostics, 2015, 17, 64-75.	2.8	65
44	Clinical Tumor Sequencing: An Incidental Casualty of the American College of Medical Genetics and Genomics Recommendations for Reporting of Incidental Findings. Journal of Clinical Oncology, 2014, 32, 2203-2205.	1.6	36
45	Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In Between. American Journal of Human Genetics, 2014, 94, 818-826.	6.2	342
46	Translating Genomics for Precision Cancer Medicine. Annual Review of Genomics and Human Genetics, 2014, 15, 395-415.	6.2	63
47	Identification of Targetable FGFR Gene Fusions in Diverse Cancers. Cancer Discovery, 2013, 3, 636-647.	9.4	614
48	Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nature Genetics, 2013, 45, 180-185.	21.4	662
49	Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nature Genetics, 2013, 45, 1446-1451.	21.4	925
50	Advancing Precision Medicine for Prostate Cancer Through Genomics. Journal of Clinical Oncology, 2013, 31, 1866-1873.	1.6	84
51	Implementing personalized cancer genomics in clinical trials. Nature Reviews Drug Discovery, 2013, 12, 358-369.	46.4	267
52	Cancer genomics meets clinical trials: the challenge ahead. Personalized Medicine, 2012, 9, 459-461.	1.5	3
53	Managing resistance in chronic myeloid leukemia. Blood Reviews, 2011, 25, 279-290.	5.7	56
54	Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study. Science Translational Medicine, 2011, 3, 111ra121.	12.4	531

#	ARTICLE	IF	CITATIONS
55	IFN- γ gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice. <i>Blood</i> , 2005, 105, 1558-1565.	1.4	35
56	Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease. <i>Blood</i> , 2005, 105, 894-901.	1.4	75
57	Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies. <i>Blood</i> , 2005, 105, 1114-1120.	1.4	27
58	IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease. <i>Blood</i> , 2005, 106, 2433-2435.	1.4	45
59	A Human CD34(+) Subset Resides in Lymph Nodes and Differentiates into CD56bright Natural Killer Cells. <i>Immunity</i> , 2005, 22, 295-304.	14.3	331
60	Combination Immunotherapy of B-Cell Non-Hodgkin's Lymphoma with Rituximab and Interleukin-2. <i>Clinical Cancer Research</i> , 2004, 10, 6101-6110.	7.0	74
61	Failed Adoptive Immunotherapy with Tumor-Specific T Cells. <i>Cancer Research</i> , 2004, 64, 8062-8067.	0.9	66
62	Selective Efficacy of Depsipeptide in a Xenograft Model of Epstein-Barr Virus-Positive Lymphoproliferative Disorder. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1447-1457.	6.3	29
63	A Novel Human CD34(+) Subset That Constitutively Expresses the High Affinity Interleukin-2 Receptor Traffics to Lymph Nodes and Differentiates into CD56Bright Natural Killer Cells.. <i>Blood</i> , 2004, 104, 314-314.	1.4	13
64	Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. <i>Cancer Research</i> , 2003, 63, 965-71.	0.9	70
65	Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8+ T-cell restoration. <i>Blood</i> , 2002, 100, 2341-2348.	1.4	54